PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review)
Oncology Reports · 2026
DOI: 10.3892/or.2026.9208 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reports, 2026. Verfasst von Yuchen He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, Chengdu University, Chengdu, Sichuan 610106, P.R. China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Neoplasms, Antineoplastic Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, Chengdu University, Chengdu, Sichuan 610106, P.R. China.
- Department of Food Science and Engineering, Chengdu University, Chengdu, Sichuan 610106, P.R. China.
- Department of Ophthalmology, 474 Hospital of Urumqi, Urumqi, Xinjiang Uyghur Autonomous Region 830000, P.R. China.
Zitieren
APA
He, Y., Lou, J., Huang, Y., Deng, W., & Cai, X. (2026). PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review). Oncology Reports. https://doi.org/10.3892/or.2026.9208
Vancouver
He Y, Lou J, Huang Y, Deng W, Cai X. PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review). Oncology Reports. 2026. doi:10.3892/or.2026.9208
BibTeX
@article{He2026,
author = {He, Yuchen and Lou, Jiayi and Huang, Yijing and Deng, Wen and Cai, Xuehong},
title = {PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review)},
journal = {Oncology Reports},
year = {2026},
doi = {10.3892/or.2026.9208}
}
EUVIMED